An Independent Validation Study of Candidate microRNAs as
Predictive Biomarkers for Bevacizumab-based Therapy in Patients
With Metastatic Colorectal Cancer

J 2021

An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer

KISS, David, Táňa MACHÁČKOVÁ, Kamila SOUČKOVÁ, Pavel FABIAN, Iveta KŘEPELKOVÁ et. al.

Basic information

Original name

An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer

Authors

KISS, David (203 Czech Republic), Táňa MACHÁČKOVÁ (203 Czech Republic, belonging to the institution), Kamila SOUČKOVÁ (203 Czech Republic, belonging to the institution), Pavel FABIAN (203 Czech Republic), Iveta KŘEPELKOVÁ (203 Czech Republic), M. SVOBODA and Igor KISS (203 Czech Republic, guarantor, belonging to the institution)

Edition

In vivo, ATHENS, Greece : International Institute of Anticancer Research, 2021, 0258-851X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.406

RIV identification code

RIV/00216224:14740/21:00120233

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.21873/invivo.12567

UT WoS

000691746000013

Keywords in English

Bevacizumab; metastatic colorectal cancer; microRNA; progression-free survival; predictive biomarker; validation

Abstract

V originále

Background/Aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. Patients and Methods: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. Results: Expression levels of candidate miRNA biomarkers (miR-92b3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival

Links

NU20-03-00127, research and development project

Name: Dlouhé nekódující RNA v exozómech jako biomarkery umožňující neinvazivní časnou detekci kolorektálního karcinomu

Investor: Ministry of Health of the CR, Exosomal long non-coding RNAs as non-invasive biomarkers for early detection of colorectal cancer, Subprogram 1 - standard

90091, large research infrastructures

Name: NCMG

Citovat

KISS, David, Táňa MACHÁČKOVÁ, Kamila SOUČKOVÁ, Pavel FABIAN, Iveta KŘEPELKOVÁ, M. SVOBODA and Igor KISS. An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer. In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2021, vol. 35, No 5, p. 2809-2814. ISSN 0258-851X. Available from: https://dx.doi.org/10.21873/invivo.12567.

@article{1837296,
   author = {Kiss, David and Macháčková, Táňa and Součková, Kamila and Fabian, Pavel and Křepelková, Iveta and Svoboda, M. and Kiss, Igor},
   article_location = {ATHENS},
   article_number = {5},
   doi = {http://dx.doi.org/10.21873/invivo.12567},
   keywords = {Bevacizumab; metastatic colorectal cancer; microRNA; progression-free survival; predictive biomarker; validation},
   language = {eng},
   issn = {0258-851X},
   journal = {In vivo},
   title = {An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer},
   url = {https://iv.iiarjournals.org/content/35/5/2809},
   volume = {35},
   year = {2021}
}

TY  - JOUR
ID  - 1837296
AU  - Kiss, David - Macháčková, Táňa - Součková, Kamila - Fabian, Pavel - Křepelková, Iveta - Svoboda, M. - Kiss, Igor
PY  - 2021
TI  - An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer
JF  - In vivo
VL  - 35
IS  - 5
SP  - 2809-2814
EP  - 2809-2814
PB  - Greece : International Institute of Anticancer Research
SN  - 0258851X
KW  - Bevacizumab
KW  - metastatic colorectal cancer
KW  - microRNA
KW  - progression-free survival
KW  - predictive biomarker
KW  - validation
UR  - https://iv.iiarjournals.org/content/35/5/2809
N2  - Background/Aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. Patients and Methods: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. Results: Expression levels of candidate miRNA biomarkers (miR-92b3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival
ER  -

KISS, David, Táňa MACHÁČKOVÁ, Kamila SOUČKOVÁ, Pavel FABIAN, Iveta KŘEPELKOVÁ, M. SVOBODA and Igor KISS. An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2021, vol.~35, No~5, p.~2809-2814. ISSN~0258-851X. Available from: https://dx.doi.org/10.21873/invivo.12567.

Detailed Information on Publication Record